Antibody-mediated blockade of the PD1-PD-L1 interaction has demonstrated remarkable clinical efficacy for many cancer patients and stimulated the research aiming at identifying additional targetable immunosuppressive mechanisms in the tumor microenvironment [7]. Here, CD274 is linked to neoplasm.